Vassilios I. Avramis
CHLA Hematology/Oncology USC-Keck School of Medicine
Los Angeles
CA 90027
USA
Name/email consistency: high
- Immunogenicity of native or pegylated E. coli and Erwinia asparaginases assessed by ELISA and surface plasmon resonance (SPR-biacore) assays of IgG antibodies (Ab) in sera from patients with acute lymphoblastic leukemia (ALL). Avramis, V.I., Avramis, E.V., Hunter, W., Long, M.C. Anticancer Res. (2009)
- Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia. Avramis, V.I., Tiwari, P.N. Int. J. Nanomedicine (2006)
- Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future. Avramis, V.I., Panosyan, E.H. Clin. Pharmacokinet (2005)
- A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. Avramis, V.I., Sencer, S., Periclou, A.P., Sather, H., Bostrom, B.C., Cohen, L.J., Ettinger, A.G., Ettinger, L.J., Franklin, J., Gaynon, P.S., Hilden, J.M., Lange, B., Majlessipour, F., Mathew, P., Needle, M., Neglia, J., Reaman, G., Holcenberg, J.S., Stork, L. Blood (2002)
- Synergistic antiviral effect of PEG-asparaginase (ONCASPAR), with protease inhibitor alone and in combination with RT inhibitors against HIV-1 infected T-cells: a model of HIV-1-induced T-cell lymphoma. Avramis, V.I., Kwock, R., Avramis, I.A., Cohen, L.J., Inderlied, C. In. Vivo (2001)
- Taxotere and vincristine inhibit the secretion of the angiogenesis inducing vascular endothelial growth factor (VEGF) by wild-type and drug-resistant human leukemia T-cell lines. Avramis, I.A., Kwock, R., Avramis, V.I. Anticancer Res. (2001)